{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:04:08Z","timestamp":1784282648866,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Personalized nutrition, also referred to as precision nutrition, is an emerging approach that integrates genetic, metabolic, phenotypic, behavioral, and environmental characteristics to develop individualized dietary strategies. Obesity, metabolic syndrome (MetS), and metabolic dysfunction-associated steatotic liver disease (MASLD) represent interconnected disorders with substantial inter-individual variability in disease development, metabolic risk, and response to dietary interventions. Although body mass index (BMI) remains widely used for obesity classification, it does not adequately capture differences in body composition, fat distribution, or metabolic health. Consequently, individuals with normal-weight obesity (NWO), characterized by excessive body fat accumulation despite a normal BMI, may remain unidentified despite increased cardiometabolic risk.This narrative review critically evaluates the current evidence on the potential role of personalized nutrition in the prevention and management of obesity, MetS, MASLD, and related cardiometabolic abnormalities. Particular attention is given to five major domains: nutrigenetics, gut microbiota, metabolic phenotyping, body composition assessment, and digital health technologies, with emphasis on their current clinical applicability and limitations. Methods: A structured narrative review was performed using PubMed, Scopus, and Web of Science to identify English-language studies (2003\u20132026) on personalized nutrition in obesity, normal-weight obesity, metabolic syndrome, and MASLD. Eligible studies were selected according to predefined inclusion and exclusion criteria, and 31 publications were included in the qualitative synthesis. Results: Current evidence suggests that personalized nutrition strategies may contribute to improvements in body weight regulation, insulin sensitivity, lipid metabolism, and liver-related outcomes; however, the magnitude and consistency of these effects remain variable. The integration of genetic, metabolic, microbiome, and phenotypic information may improve individual risk stratification and help identify high-risk groups, including individuals with NWO who may not be recognized through BMI-based assessment alone. Emerging approaches involving multi-omics technologies, microbiome profiling, wearable devices, continuous glucose monitoring, and artificial intelligence-based tools provide promising opportunities for individualized dietary interventions. Nevertheless, limitations related to methodological heterogeneity, insufficient standardization, limited external validation, and the scarcity of long-term pragmatic clinical trials currently restrict their routine implementation. Conclusions: Personalized nutrition represents a promising but still evolving approach for addressing obesity and its metabolic complications, including MetS and MASLD. While the integration of biological, phenotypic, and digital information may support more targeted dietary recommendations, current evidence does not yet fully establish the clinical effectiveness and cost-effectiveness of these approaches in routine care. Future large-scale, longitudinal, and well-designed randomized controlled trials are required to determine which personalized nutrition strategies provide clinically meaningful benefits and for which patient populations.<\/jats:p>","DOI":"10.3390\/nu18142345","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:00:52Z","timestamp":1784278852000},"page":"2345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond BMI: Personalized Nutrition in Obesity, Normal-Weight Obesity, Metabolic Syndrome, and MASLD"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-8894","authenticated-orcid":false,"given":"Aldona","family":"Wierzbicka-Ruci\u0144ska","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, The Children\u2019s Memorial Health Institute, Aleja Dzieci Polskich 20, 04-730 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ijo.2008.102","article-title":"Global burden of obesity in 2005 and projections to 2030","volume":"32","author":"Kelly","year":"2008","journal-title":"Int. J. Obes."},{"key":"ref_2","first-page":"S176","article-title":"Obesity: Definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am. J. Manag. Care"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tremmel, M., Gerdtham, U.G., Nilsson, P.M., and Saha, S. (2017). Economic burden of obesity: A systematic literature review. Int. J. Environ. Res. Public Health, 14.","DOI":"10.3390\/ijerph14040435"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurheartj\/ehp487","article-title":"Normal weight obesity: A risk factor for cardiometabolic dysregulation and cardiovascular mortality","volume":"31","author":"Somers","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1038\/ijo.2008.87","article-title":"BMI-related errors in the measurement of obesity","volume":"32","author":"Rothman","year":"2008","journal-title":"Int. J. Obes."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pcad.2013.10.003","article-title":"The concept of normal weight obesity","volume":"56","author":"Oliveros","year":"2014","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.amepre.2011.10.026","article-title":"Obesity and severe obesity forecasts through 2030","volume":"42","author":"Finkelstein","year":"2012","journal-title":"Am. J. Prev. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Luhar, S., Tim\u00e6us, I.M., Jones, R., Cunningham, S., Patel, S.A., Kinra, S., Clarke, L., and Houben, R. (2020). Forecasting the prevalence of overweight and obesity in India to 2040. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229438"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/obr.12570","article-title":"Overweight but unseen: A review of the underestimation of weight status","volume":"18","author":"Robinson","year":"2017","journal-title":"Obes. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/oby.22654","article-title":"Plasma high-resolution metabolomics differentiates adults with normal weight obesity from lean individuals","volume":"27","author":"Bellissimo","year":"2019","journal-title":"Obesity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/osp4.4","article-title":"Normal weight adiposity in a Swedish population","volume":"1","author":"Berg","year":"2015","journal-title":"Obes. Sci. Pract."},{"key":"ref_12","first-page":"158758","article-title":"Insulin resistance of normal weight central obese adolescents in Korea","volume":"2015","author":"Cho","year":"2015","journal-title":"Int. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/cen.12162","article-title":"Normal weight obesity in Korean adults","volume":"80","author":"Kim","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.numecd.2018.06.015","article-title":"Prevalence and cardiometabolic risks of normal weight obesity in Chinese population","volume":"28","author":"Jia","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Madeira, F.B., Silva, A.A., Veloso, H.F., Goldani, M.Z., Kac, G., Cardoso, V.C., Bettiol, H., and Barbieri, M.A. (2013). Normal weight obesity is associated with metabolic syndrome and insulin resistance in young adults from a middle-income country. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060673"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11883-014-0464-7","article-title":"Normal-weight obesity and cardiovascular health","volume":"16","author":"Jean","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.5604\/12321966.1226858","article-title":"Metabolic syndrome in normal weight individuals","volume":"23","author":"Suliga","year":"2016","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1139\/h06-092","article-title":"Metabolically obese normal-weight subjects","volume":"32","author":"Conus","year":"2007","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2015.11.001","article-title":"Personalized nutrition by prediction of glycemic responses","volume":"163","author":"Zeevi","year":"2015","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/s41591-020-0934-0","article-title":"Human postprandial responses to food and potential for precision nutrition","volume":"26","author":"Berry","year":"2020","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41591-020-01183-8","article-title":"Microbiome and metabolic phenotyping Microbiome connections with host metabolism and habitual diet from 1098 deeply phenotyped individuals","volume":"27","author":"Asnicar","year":"2021","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.2337\/dc21-0162","article-title":"Personalized Postprandial Glucose Response\u2013Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes","volume":"44","author":"Godneva","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ajcn\/88.4.922","article-title":"Manipulation of lipid bioaccessibility of almond seeds influences postprandial lipemia in healthy human subjects","volume":"88","author":"Berry","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: A patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/oby.23448","article-title":"Nutrition for precision health: The time is now","volume":"30","author":"Qi","year":"2022","journal-title":"Obesity"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e70023","DOI":"10.1111\/ijpo.70023","article-title":"Mediterranean diet and obesity polygenic risk interaction on adiposity in European children: The IDEFICS\/I.Family Study","volume":"20","author":"Drouard","year":"2025","journal-title":"Pediatr. Obes."},{"key":"ref_28","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2026.01.047","article-title":"Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"171","author":"Kanwal","year":"2026","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"bmj.k2173","DOI":"10.1136\/bmj.k2173","article-title":"Personalised nutrition and health","volume":"361","author":"Ordovas","year":"2018","journal-title":"BMJ"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/14\/2345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:16:20Z","timestamp":1784279780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/14\/2345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["nu18142345"],"URL":"https:\/\/doi.org\/10.3390\/nu18142345","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}